TTP: the rare blood-clotting emergency that is now very treatable
Last updated September 3, 2026.
Thrombotic thrombocytopenic purpura (TTP) is the rare blood disorder where the tiny clots form throughout the small vessels: the platelets consumed (the count crashing: the bruising-and-bleeding kind), the red cells shredded (the anemia), and the organs starved (the brain, the kidneys, the heart): the medical emergency that was once near-uniformly fatal and is now the 80-90-percent-survivable row when treated fast. The cause in the most: the antibody disabling the ADAMTS13 enzyme (the clot-protein cutter: the acquired-autoimmune kind), and the treatment (the plasma exchange plus the immune-suppression: the rituximab-and-steroids rows) started the same-day saves the lives.
What does it look like?
The cluster (the often-days-kind build): the unexplained bruising-and-pinpoint-bleeding (the petechiae: the gums-nosebleeds), the fatigue-and-pallor (the anemia), the neurological shifts (the headaches, the confusion, the speech-or-weakness rows: the stroke-mimicking kind), the dark urine, the jaundice, and the fever sometimes. The bloods show the picture (the platelets crashed, the red-cells-fragmented, the LDH high), and the ADAMTS13 activity confirms.
Why does it happen?
The acquired-autoimmune kind in the great majority (the antibody blocking the ADAMTS13: the clot-protein strands un-cut, the clots forming everywhere), the rare inherited kind (the Upshaw-Schulman row: the enzyme missing from the birth), and the trigger-kind rows (the pregnancy, the infections, the some-drugs: the flares often following the stressors). The relapses occur in the substantial minority: the monitoring lifelong.
How is it treated?
- The plasma exchange urgently: the blood out, the plasma replaced (the donor-plasma row: the antibody diluted, the enzyme restored: the daily until the platelets recover: the life-saving kind).
- The immune-suppression: the steroids immediately, the rituximab (the antibody-production turned off: the relapse-risk reduced), the caplacizumab (the clot-formation blocked while the enzyme recovers).
- The relapse watched-for: the ADAMTS13 monitored (the dropping activity preemptively treated with the rituximab in the many centers: the preventing-the-flare row).
- The recovery-and-aftermath: the weeks-to-months row (the fatigue, the memory-and-mood rows real: the rehabilitation needed for the some), and the specialist-clinic follow-up.
When is it an emergency?
The TTP-suspicion is the same-day-emergency row: the unexplained bruising-pinpoint-bleeding with the fatigue-or-confusion goes to the ER now (the hours-kind urgency: the untreated-days are the dangerous row). For the known-TTP survivors: the any return of the bruising, the dark urine, the headaches, or the confusion is the immediate-review row. Pymander's escalation routing is built and tested specifically for this class of decision; see the safety architecture working paper.
What a Pymander AI doctor consult looks like
Illustrative example, not a real member's messages.
Common questions
What are her chances? Be honest with me.
The straight row: the treated-promptly TTP carries the 80-90-percent survival (the plasma exchange transformed it from the near-uniformly-fatal kind), and the being-in-the-ICU-on-the-daily-exchange is exactly where the surviving rows happen: the days-to-weeks row (the platelet count rising the turning-point the team watches). The confusion is the frightening-but-recognized feature (the brain-row involvement: the usually-recovering kind as the treatment works), and the honest remainder: the severe-kind rows exist, and the team's day-by-day numbers tell her row. Asking for the daily-platelet-trend is the legitimate family question.
Why did this happen to her? She was healthy.
The autoimmune ambush row: the most TTP is the acquired kind (the immune system suddenly making the antibody against the ADAMTS13 enzyme: the clot-protein scissors disabled: the tiny clots forming everywhere), striking the healthy people (the young-middle-aged adults, the women somewhat more), with the triggers sometimes visible (the infections, the pregnancy, the some-drugs) and the often-nothing-found row. It is the lightning-strike kind: the nobody-caused-it row, and the healthy-before does not predict the severity: the treatment-speed does.
What exactly does the plasma exchange do?
The replace-the-plasma row: her blood drawn through the machine, the plasma (carrying the harmful antibody) removed, the donor plasma (carrying the working enzyme) returned: the daily sessions (the hours-each kind) until the platelets recover-and-hold, simultaneously the steroids-plus-rituximab switch off the antibody production (the treating-the-source row), and the caplacizumab-kind drug blocks the clot-forming meanwhile. The combination is the transformative row: the mechanism-targeted treatment in the full sense.
Will it come back after she recovers?
The honest row: the relapses occur in the substantial minority (the one-third-ish kind: the months-to-years kind of timing), which is why the survivorship includes the monitoring (the ADAMTS13-activity bloods at the intervals: the dropping-kind caught BEFORE the symptoms: the preemptive rituximab row preventing many flares), the warning-signs learned (the bruising-pinpoint-bleeding, the dark urine, the headaches, the confusion: the same-day-review row), and the trigger-kind rows managed (the pregnancy needs the specialist-planning kind). The relapse-risk declines over the years but the watching stays.
What is recovery like? Will she be herself?
The weeks-to-months honest row: the physical recovery comes first (the platelets-and-counts normalizing, the strength returning over the weeks), the fatigue-and-memory rows are the real kind for the many (the brain-involvement survivors: the concentration-mood rows: the reported row), the rehabilitation helps (the neuro-kind follow-up where the needed), and the most return to the full-lives kind (the work, the family rows), with the some carrying the longer-tail symptoms (the naming-them-to-the-team row: the support exists, including the TTP survivor groups: the rare-disease community helpful).
Should the family be tested? Is it inherited?
The mostly-no row: the acquired-autoimmune kind (her row, the great majority) is the not-inherited kind (the family screening not indicated), while the rare inherited kind (the Upshaw-Schulman row: the usually-presenting-in-childhood kind: the different pattern) does run in the families: her antibody-testing row distinguishes them, and the team will say which row she is on. For the acquired-kind rows: the relatives carry no meaningful extra risk.